Stereotaxis, Inc.

STXSSEC EDGAR

Electromedical & Electrotherapeutic Apparatus(DE)CIK: 1289340

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$26.9M	$26.8M	$28.1M	$35.0M	$26.6M
Cost of Revenue	$12.3M	$11.9M	$9.7M	$11.8M	$7.7M
Gross Profit	$14.6M	$14.9M	$18.5M	$23.2M	$19.0M
Research and Development Expense	$9.8M	$10.3M	$10.6M	$10.2M	$8.1M
Operating Expenses	$39.3M	$36.7M	$37.2M	$36.1M	$25.7M
Operating Income (Loss)	-$24.7M	-$21.8M	-$18.8M	-$12.9M	-$6.7M
Interest Expense	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$46.7M	$41.9M	$53.4M	$61.0M	$55.5M
Assets, Current	$26.4M	$33.3M	$43.2M	$51.4M	$52.7M
Cash and Cash Equivalents, at Carrying Value	$12.2M	$19.8M	$8.6M	$38.7M	$43.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$3.8M	$3.8M	$5.1M	$5.4M	$3.5M
Inventory, Net	$8.3M	$8.4M	$7.9M	$4.4M	$3.3M
Liabilities	$35.3M	$20.0M	$21.5M	$21.6M	$15.2M
Liabilities, Current	$21.6M	$13.2M	$14.3M	$13.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$8.5M	-$9.1M	-$8.4M	-$2.9M	-$3.5M
Net Cash Provided by (Used in) Investing Activities	$74.0K	$19.8M	-$22.1M	-$1.4M	-$70.9K
Net Cash Provided by (Used in) Financing Activities	$297.0K	$81.0K	$220.0K	$547.0K	$17.3M
Payments of Dividends	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)